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Abstract
Background: Most cases of disseminated carcinomatosis of the bone marrow (DCBM) arise from gastric cancer.
DCBM from pancreatic cancer is very rare. We herein present a case of DCBM from pancreatic cancer.
Case presentation: A 57-year-old man was referred to our hospital for severe lumbago. Laboratory data indicated
that he suffered from disseminated intravascular coagulation (DIC). Non-contrast abdominal computed tomography
(CT) revealed multiple bone masses but no other abnormal findings. Left iliac bone marrow biopsy revealed poorly
differentiated adenocarcinoma cells. Positron emission tomography (PET)-CT showed diffuse abnormal uptake in the
bones and tail of the pancreas. Contrast whole-body CT showed a tumor measuring approximately 28 mm in diameter
with poor enhancement in the tail of the pancreas. The patient’s final diagnosis was pancreatic cancer located in the tail
of the pancreas with diffuse bone metastases and DIC. His DCBM was thus believed to originate from the pancreatic
cancer. He succumbed to the disease approximately 2 months after admission to our hospital.
Conclusion: We herein describe a case of pancreatic cancer located in the tail of the pancreas with diffuse bone
metastases and DIC, which, in our case, was DCBM. Therefore, in cases of DCBM with an unknown primary tumor,
pancreatic cancer should be considered during differential diagnosis.
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Background
Disseminated carcinomatosis of the bone marrow (DCBM)
caused by solid tumors is often accompanied by dissemi-
nated intravascular coagulation (DIC) [1]. The prognosis of
patients with DCBM is generally very poor [2]. Ap-
proximately 80–90 % of all DCBM cases are found
in stomach cancer patients. [3]. However, DCBM
arising from pancreatic cancer is extremely rare. We
herein report the case of a 57-year-old man who had
pancreatic cancer located in the tail of the pancreas
with diffuse bone metastases and DIC.
Case presentation
Case description
A 57-year-old man was referred to our hospital for severe
lumbago. His symptoms appeared approximately 3 months
prior to referral. After experiencing such symptoms for
about a month, the patient consulted an orthopedist. A
lumbar spinal radiography showed no significant findings.
Despite treatment for pain relief, his lumbago persisted. At
presentation, the patient reported no particular past
medical history or known allergies. His medication included
oxycodone hydrochloride hydrate, loxoprofen sodium
hydrate, rebamipide, prochlorperazine maleate, and magne-
sium oxide. He did not smoke or consume alcohol, and
worked as a designer. His mother had diabetes mellitus,
hypertension, and hepatocellular carcinoma, and his sister
had colon cancer. On physical examination, the patient
weight 82 kg and was 174 cm tall. His blood pressure was
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189/128 mmHg; his pulse was 92 beats per minute; body
temperature was 36.9 °C; respiratory rate was 18 breaths
per minute, and the oxygen saturation level was 98 % while
breathing ambient air. No swelling of the lymph nodes was
palpable. His physical examination was otherwise normal.
Laboratory data showed a white blood cell count of
11,100/mm3, platelet count of 73,000/mm3, international
normalized ratio for prothrombin time of 1.15, fibrinogen
level of 102 mg/dL, fibrin degradation products of
65.7 μg/mL, d-dimer level of 18.1 μg/mL, antithrombin-
III activity of 61 %, C reactive protein level of 3.63 mg/dL,
creatinine level of 1.32 mg/dL, calcium level of 11.3 mg/
dL, aspartate aminotransferase level of 164 U/L, alanine
aminotransferase level of 119 U/L, alkaline phosphatase
level of 547 U/L, and lactate dehydrogenase level of 552
U/L. Other test results are shown in Table 1. These
laboratory data suggested that the patient had DIC.
Abdominal ultrasonography showed mild splenomegaly.
Non-contrast chest computed tomography (CT), gastro-
intestinal endoscopy, and colonoscopy detected no
abnormal findings. Non-contrast abdominal CT revealed
multiple bone masses (Fig. 1); however, no tumors were
found in the liver, adrenal glands, kidneys, bladder,
prostate, or pancreas. Therefore, a bone marrow
biopsy was performed at the left iliac, revealing poorly
differentiated adenocarcinoma cells (Fig. 2). Immuno-
histochemical studies of the biopsy specimen showed
positivity for keratin 7, carcinoembryonic antigen
(CEA), and cancer antigen (CA) 19-9; negativity for
prostatic acid phosphatase (PAP) and napsin A, while
inconclusive for keratin 20 and thyroid transcription
factor (TTF)-1. Positron emission tomography (PET)-CT
disclosed diffuse abnormal uptake in the bones and tail of
the pancreas (Fig. 3), and contrast enhanced whole-body
CT depicted a tumor of approximately 28 mm in diameter
with poor enhancement in the pancreatic tail (Fig. 4). The
patient’s final diagnosis was pancreatic cancer located in
the tail of the pancreas with diffuse bone metastases and
DIC. His DCBM was thus believed to originate from the
pancreatic cancer.
We administered nafamostat mesilate to treat DIC and
opioid analgesics to relieve the patient’s lumbago and sharp
osteocopic pain. However, we were unable to administer
systemic chemotherapy owing to his poor condition. The
patient’s general status rapidly deteriorate, and he was
transferred to a palliative care unit (PCU). Laboratory data
at discharge are shown in Table 1. He died at the PCU
approximately 2 months after admission to our hospital.
Discussion
A pathological condition derived from carcinoma and
diffuse bone metastases with DIC was first reported by
Jarcho in 1936 [4]. Hayashi et al. later defined such a
pathological condition with DIC or microangiopathic
hemolytic anemia as DCBM [1]. Almost all the previ-
ously published reports have shown that DCBM results
from gastric cancer, colon cancer, lung cancer, and
breast cancer [5]. To the best of our knowledge, only
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Total bilirubin (mg/dL) 1.2
Direct bilirubin (mg/dL) 0.5
Asparate aminotransferase (U/L) 164
Alanine aminotransferase (U/L) 119
Alkaline phosphatase (U/L) 547 1012
Lactate dehydrogenase (U/L) 552 608
Carcinoembryonic antigen (ng/mL) 23.6
Carbohydrate antigen 19-9 (U/mL) 72836
Span-1 (U/mL) 5200
DUPAN-2 (U/mL) 440
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one prior report has described pancreatic cancer as the
origin of DCBM [6]. In the present case, contrast whole-
body CT revealed a tumor with poor enhancement in
the tail of the pancreas and multiple bone masses. No
other abnormal structures were identified by CT, gastro-
intestinal endoscopy, or colonoscopy, whereas PET-CT
demonstrated diffuse abnormal skeletal uptake. Labora-
tory data in the above-mentioned case showed marked
elevation of Span-1 and DUPAN-2 and DIC, while the
left iliac bone marrow biopsy revealed adenocarcinoma
cells. Such findings were probably indicative of pancre-
atic cancer with DCBM. The condition of our patient
was very severe at admission, although his tumor size
was significantly smaller than that in the previously
reported case (28 mm vs. 55 mm) [6], and he died within
2 months of diagnosis. A young age and poorly differen-
tiated carcinoma have been suggested to be associated
with poor prognosis in gastric cancer cases with DCBM
Fig. 1 Non-contrast abdominal computed tomography (CT) images. a: Multiple bone masses; b: Multiple bone masses (black arrowheads)
from the abdominal area
Fig. 2 Bone marrow biopsy. Hematoxylin and eosin staining of
the bone marrow biopsy performed at the left iliac revealed
adenocarcinoma cells (×400, black arrowheads)
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[1, 7]. Our patient was diagnosed at 57 years of age and
had poorly differentiated carcinoma, which might
explain his extremely poor prognosis despite a small
pancreatic tumor size.
A previous report indicates that the tumor detection
rate with non-contrast CT was 23 % when tumor size
was less than 20 mm, 59 % for tumors measuring less
than 40 mm, and 100 % in cases of tumors measuring
more than 40 mm [8]. In the present case, the tumor
size was 28 mm, and it was undetectable via non-
contrast CT. It was subsequently found by PET and
contrast-enhanced CT imaging.
Fig. 3 PET-CT studies. a: Diffuse skeletal uptake; b: Abnormal uptake in the tail of the pancreas
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While the serum CA19-9 levels were normal in cases of
gastric cancer with DCBM [9–12], the serum CA19-9
levels were markedly elevated in cases of pancreatic cancer
with DCBM in the present study as well as those in a pre-
vious study [6]. Although the mechanism for this finding
is unknown, the extremely high CA 19-9 levels might be
helpful in the early diagnosis of pancreatic cancer with
DCBM before the histopathological examination results
are obtained.
Exacerbation of DCBM occurs rapidly, and the mean
survival time is 4.6 months after the onset of DCBM [9].
A proper diagnosis and timely administration of chemo-
therapy and treatment of DIC are crucial to prolong
survival [13]. Pancreatic tumors are occasionally challen-
ging to detect with non-contrast CT. Therefore, it is
important to consider the pancreas as a possible origin of
DCBM and perform contrast-enhanced CT when multiple
bone metastases are observed.
Conclusions
We herein describe a case of pancreatic cancer located in
the tail of the pancreas with diffuse bone metastases and
DIC, which, in our case, was DCBM. This is the first case
report to demonstrate DCBM arising from the small
pancreatic cancer, to the best of our knowledge. Therefore,
in cases of DCBM with an unknown primary tumor,
pancreatic cancer should be considered during differential
diagnosis to properly identify the primary site for the timely
administration of chemotherapy and DIC treatment.
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